These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2272029)

  • 1. Novel anthracycline analogs.
    Grandi M; Pezzoni G; Ballinari D; Capolongo L; Suarato A; Bargiotti A; Faiardi D; Spreafico F
    Cancer Treat Rev; 1990 Sep; 17(2-3):133-8. PubMed ID: 2272029
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
    Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
    Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modulation of anthracycline resistance by reserpine in P388 leukemia cells].
    Shibata H; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
    Nihon Yakurigaku Zasshi; 1991 Jul; 98(1):1-6. PubMed ID: 1889760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anthracycline antibiotics and their derivatives--inhibitors of topoisomerase I].
    Dezhenkova LG; Teviashova AN; Olsuf'eva EN; Treshchalin ID; Shtil' AA; Preobrazhenskaia MN
    Bioorg Khim; 2008; 34(3):430-2. PubMed ID: 18672696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Study of Pharmacological Properties of Doxorubicin-NPh.
    Nemtsova ER; Tikhonova EG; Bezborodova OA; Pankratov AA; Venediktova JB; Korotkevich EI; Kostryukova LV; Tereshkina JA
    Bull Exp Biol Med; 2020 Oct; 169(6):778-782. PubMed ID: 33123920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Augmentation of pirarubicin cytotoxicity by chlorpromazine in doxorubicin-resistant mouse P388 leukemia cells].
    Shibata H; Sano F; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
    Yakugaku Zasshi; 1990 Sep; 110(9):678-81. PubMed ID: 2262880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
    Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concepts for controlling drug-resistant tumor cells.
    Schabel FM; Skipper HE; Trader MW; Laster WR; Corbett TH; Griswold DP
    Eur J Cancer (1965); 1980; Suppl 1():199-211. PubMed ID: 6947891
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of antitumor activity of ORG 5895, a 11 beta-aziridinylmethyl derivative of estradiol, on the MXT mammary tumor and the P388 leukemia.
    Devleeschouwer N; Leclercq G; Danguy A; Atassi G
    Cancer Chemother Pharmacol; 1982; 8(3):315-6. PubMed ID: 7127663
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines.
    Liu QY; Tan BK
    Life Sci; 2000; 67(10):1207-18. PubMed ID: 10954054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
    Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
    Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
    Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
    Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
    Acton EM; Tong GL
    J Med Chem; 1981 Jun; 24(6):669-73. PubMed ID: 7252976
    [No Abstract]   [Full Text] [Related]  

  • 18. N-(2-hydroxyethyl)doxorubicin from hydrolysis of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin.
    Acton EM; Tong GL; Smith TH; Taylor DL; Streeter DG; Peters JH; Gordon GR; Filppi JA; Wolgemuth RL; Giuliani FC
    J Med Chem; 1986 Oct; 29(10):2120-2. PubMed ID: 3761328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tunicamycin on anthracycline resistance in P388 murine leukemia cells.
    Chou TH; Kessel D
    Biochem Pharmacol; 1981 Nov; 30(22):3134-6. PubMed ID: 6950722
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative cytotoxicities of various morpholinyl anthracyclines.
    Streeter DG; Taylor DL; Acton EM; Peters JH
    Cancer Chemother Pharmacol; 1985; 14(2):160-4. PubMed ID: 3971481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.